【医学课件】ease研究ppt课件.ppt

1、Ezetimibe Add-on to Statin Therapy for Effectiveness Trial,Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Thomas Pearson,EASE Trial,天马行空官方博客： ；QQ:1318241189；QQ群：175569632,Endpoints (6 weeks): Percent change from baseline in LDL cholesterol in the overall popula

2、tion and by NCEP ATP III CHD risk category,EASE Trial,Presented at ACC Scientific Sessions 2004,3,030 Patients with low-density lipoprotein (LDL) cholesterol exceeding National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III goals. Randomized, double-blind, multicenter,Ezetimibe

3、 n=2,020,Placebo n=1,010,Treatment Added to a dose of any statin (40% atorvastatin, 29% simvastatin, 22% pravastatin, 10% other),Reduction in Triglycerides p0.001,Presented at ACC Scientific Sessions 2004,EASE Trial,A large proportion of patients in the trial had diabetes (38.4%) and metabolic syndr

4、ome by NCEP ATP III criteria (60%). Baseline LDL levels were 129 mg/dl in the overall population, 123 mg/dl in the coronary heart disease (CHD) or CHD risk equivalent group, 147 mg/dl in the multiple risk factors group, and 167 mg/dl in the 2 risk factors group. The ezetimibe arm had a larger reduct

5、ion in triglycerides and a larger increase in high-density lipoprotein (HDL) levels.,Ezetimibe,Placebo,mg/dl,Increase in High-Density Lipoprotein (HDL) p0.001,Ezetimibe,Placebo,Reduction in LDL p0.001,Presented at ACC Scientific Sessions 2004,EASE Trial,In the overall study population, a larger perc

6、ent change from baseline in LDL levels occurred in the ezetimibe arm versus placebo. The follow-up LDL level in the ezetimibe arm was 95 mg/dl. A larger percentage of patients in the ezetimibe arm reached target LDL goals. Results were similar across the different statin brands and by the prespecifi

7、ed subgroups of age group, gender, and diabetes status.,Ezetimibe,Placebo,Reached Target LDL Goals p0.001,mg/dl,Ezetimibe,Placebo,Reduction in LDL p0.001,Presented at ACC Scientific Sessions 2004,EASE Trial,Reached Target LDL Goals p0.001,mg/dl,Similar results were observed in the CHD/CHD risk equiv

8、alent subgroup, the multiple risk factor subgroup, and the 2 CHD risk factor subgroup. There were no increases in the frequency of alanine aminotransferase (ALT) 3 times upper limit of normal (ULN) (0.4% for ezetimibe vs. 0.2% for placebo), aspartate aminotransferase (AST) 3 times ULN (0.2% vs. 0.1%

9、), or creatine kinase (CK) 10 times ULN (0 in both groups).,CHD/CHD Equivalent,Multiple Risk Factor,2 CHD Risk Factor,CHD/CHD Equivalent,Multiple Risk Factor,2 CHD Risk Factor,Among patients with LDL cholesterol exceeding NCEP ATP III goals and on statin therapy, additional treatment with ezetimibe

10、was associated with a larger reduction in LDL cholesterol and a greater number of patients meeting LDL target goals compared with placebo, with no additional safety issues. The 23% larger reduction in LDL levels was higher than the 6-8% reduction usually observed by doubling the statin dose. The present trial adds to the growing body of studies showing an added benefit with ezetimibe in addition to statin therapy. Earlier trials used a sele